DK1350839T3 - Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti - Google Patents
Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microtiInfo
- Publication number
- DK1350839T3 DK1350839T3 DK02290864.4T DK02290864T DK1350839T3 DK 1350839 T3 DK1350839 T3 DK 1350839T3 DK 02290864 T DK02290864 T DK 02290864T DK 1350839 T3 DK1350839 T3 DK 1350839T3
- Authority
- DK
- Denmark
- Prior art keywords
- microti
- bovis bcg
- strains
- virulence
- enabling
- Prior art date
Links
- 241001467552 Mycobacterium bovis BCG Species 0.000 title abstract 3
- 241000187919 Mycobacterium microti Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000001018 virulence Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02290864A EP1350839B1 (en) | 2002-04-05 | 2002-04-05 | Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1350839T3 true DK1350839T3 (da) | 2010-07-12 |
Family
ID=27838170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02290864.4T DK1350839T3 (da) | 2002-04-05 | 2002-04-05 | Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7883712B2 (da) |
| EP (4) | EP1350839B1 (da) |
| AT (2) | ATE469963T1 (da) |
| AU (1) | AU2003223039A1 (da) |
| CA (1) | CA2481318C (da) |
| CY (1) | CY1110764T1 (da) |
| DE (1) | DE60236573D1 (da) |
| DK (1) | DK1350839T3 (da) |
| ES (1) | ES2346043T3 (da) |
| HK (1) | HK1059803A1 (da) |
| PT (1) | PT1350839E (da) |
| WO (1) | WO2003085098A2 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040091A1 (it) | 2004-02-19 | 2004-05-19 | Istituto Naz Per Le Malattie | Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare. |
| GB0406271D0 (en) | 2004-03-19 | 2004-04-21 | Isis Innovation | Diagnostic test |
| US8475803B2 (en) * | 2005-04-29 | 2013-07-02 | Fusion Antibodies Limited | Assays for diagnosis of tuberculosis and uses thereof |
| US8398991B2 (en) * | 2005-06-22 | 2013-03-19 | Institut Pasteur | Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG |
| GB0618127D0 (en) * | 2006-09-14 | 2006-10-25 | Isis Innovation | Biomarker |
| WO2008140598A2 (en) * | 2006-12-04 | 2008-11-20 | Bacilligen, Inc. | Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof |
| CN102413837B (zh) | 2009-04-24 | 2015-11-25 | 国立血清研究所 | 预防再激活的结核病tb疫苗 |
| WO2010132112A2 (en) * | 2009-05-14 | 2010-11-18 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
| TR201101874A2 (tr) * | 2011-02-25 | 2011-08-22 | Leyla A�An Nac�Ye | Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri. |
| GR20120100415A (el) * | 2012-08-08 | 2014-03-17 | Νικολαος Χρηστου Πουλακης | Μεθοδος αμεσης ανιχνευσης του μυκοβακτηριδιου της φυματιωσης |
| WO2014063704A2 (en) * | 2012-10-23 | 2014-05-01 | Statens Serum Institut | M. tuberculosis vaccines |
| EP3152227B1 (en) | 2014-06-03 | 2018-09-26 | Institut Pasteur | Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system |
| CN104628834B (zh) * | 2015-01-23 | 2016-03-23 | 中国疾病预防控制中心传染病预防控制所 | 一种结核感染t细胞免疫检测抗原及其应用 |
| CN104678097B (zh) * | 2015-03-10 | 2017-04-05 | 中国人民解放军军事医学科学院基础医学研究所 | 一种用于肺结核诊断的结核分枝杆菌组合抗原 |
| CN109406776B (zh) * | 2017-08-18 | 2022-02-11 | 中国科学院生物物理研究所 | 用于特异性检测结核分枝杆菌感染的蛋白Rv2818c |
| CN109406777B (zh) * | 2017-08-18 | 2022-02-18 | 中国科学院生物物理研究所 | 用于特异性检测结核分枝杆菌感染的蛋白Rv2824c |
| EP3643399B1 (de) | 2018-10-25 | 2022-04-27 | Heraeus Medical GmbH | Vorrichtung und verfahren zum bereitstellen von knochenzement |
| DE102018131266B4 (de) | 2018-12-07 | 2021-12-23 | Heraeus Medical Gmbh | Vorrichtung zum Mischen eines Knochenzements mit Hohlraum zum Monomertransfer und Verfahren zur Herstellung eines Knochenzementteigs |
| DE102018131268B4 (de) | 2018-12-07 | 2021-11-25 | Heraeus Medical Gmbh | Vorrichtung zum Mischen eines Knochenzements mit Hohlraum zum Monomertransfer |
| CN110763843B (zh) * | 2019-11-06 | 2020-09-15 | 华中农业大学 | 一种牛支原体双抗夹心elisa检测试剂盒及其应用 |
| CN116173213A (zh) * | 2023-01-16 | 2023-05-30 | 武汉大学 | Rv1977在制备抗结核分枝杆菌感染药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096879A (en) | 1978-12-18 | 2000-08-01 | Institut Pasteur | Nucleotide sequence comprising the genome of hepatitis B virus, nucleotide sequence coding the surface antigen of the hepatitis B virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby |
| DE3176404D1 (en) | 1980-04-22 | 1987-10-08 | Pasteur Institut | Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine |
| IE64006B1 (en) | 1984-10-18 | 1995-06-28 | Pasteur Institut | Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus |
| FR2682122B1 (fr) | 1991-10-03 | 1995-06-09 | Pasteur Institut | Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori. |
| FR2735478B1 (fr) | 1995-06-13 | 1997-08-22 | Pasteur Institut | Molecules polypeptidiques de stade pre-erythrocytaire du paludisme |
| FR2744724B1 (fr) | 1996-02-14 | 2002-08-02 | Pasteur Institut | Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques |
| AU8123898A (en) * | 1997-07-16 | 1999-02-10 | Institut Pasteur | A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as metho ds usingthe same |
| CA2322505A1 (en) * | 1998-03-06 | 1999-09-10 | Statens Serum Institut | Production of mycobacterial polypeptides by lactic acid bacteria |
| US6294328B1 (en) * | 1998-06-24 | 2001-09-25 | The Institute For Genomic Research | DNA sequences for strain analysis in Mycobacterium tuberculosis |
| ES2326257T3 (es) * | 1999-05-04 | 2009-10-06 | The University Of Medicine And Dentistry Of New Jersey | Proteinas expresadas por mycobacterium tuberculosis y no por bcg y su utilizacion como reactivos diagnosticos y vacunas. |
| ATE360097T1 (de) | 2002-02-25 | 2007-05-15 | Pasteur Institut | Spezifisch vom genom von mycobacterium tuberculosis deletierte sequenzen und deren verwendung in der diagnostik und als vakzine |
-
2002
- 2002-04-05 AT AT02290864T patent/ATE469963T1/de active
- 2002-04-05 DE DE60236573T patent/DE60236573D1/de not_active Expired - Lifetime
- 2002-04-05 ES ES02290864T patent/ES2346043T3/es not_active Expired - Lifetime
- 2002-04-05 EP EP02290864A patent/EP1350839B1/en not_active Expired - Lifetime
- 2002-04-05 EP EP07122295A patent/EP1914299B9/en not_active Expired - Lifetime
- 2002-04-05 PT PT02290864T patent/PT1350839E/pt unknown
- 2002-04-05 AT AT07122295T patent/ATE535600T1/de active
- 2002-04-05 DK DK02290864.4T patent/DK1350839T3/da active
-
2003
- 2003-04-01 WO PCT/IB2003/001789 patent/WO2003085098A2/en not_active Application Discontinuation
- 2003-04-01 EP EP10179423A patent/EP2302033A3/en not_active Withdrawn
- 2003-04-01 EP EP03719008A patent/EP1492867A2/en not_active Withdrawn
- 2003-04-01 CA CA2481318A patent/CA2481318C/en not_active Expired - Fee Related
- 2003-04-01 AU AU2003223039A patent/AU2003223039A1/en not_active Abandoned
- 2003-04-01 US US10/510,021 patent/US7883712B2/en not_active Expired - Fee Related
-
2004
- 2004-04-08 HK HK04102539.0A patent/HK1059803A1/xx not_active IP Right Cessation
-
2010
- 2010-09-01 CY CY20101100800T patent/CY1110764T1/el unknown
- 2010-09-21 US US12/923,432 patent/US8747866B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2302033A3 (en) | 2012-03-07 |
| DE60236573D1 (de) | 2010-07-15 |
| ATE469963T1 (de) | 2010-06-15 |
| EP1492867A2 (en) | 2005-01-05 |
| WO2003085098A2 (en) | 2003-10-16 |
| AU2003223039A1 (en) | 2003-10-20 |
| US8747866B2 (en) | 2014-06-10 |
| AU2003223039A8 (en) | 2003-10-20 |
| EP1914299B9 (en) | 2012-05-02 |
| ATE535600T1 (de) | 2011-12-15 |
| EP1350839B1 (en) | 2010-06-02 |
| CY1110764T1 (el) | 2015-06-10 |
| EP1350839A1 (en) | 2003-10-08 |
| ES2346043T3 (es) | 2010-10-08 |
| EP1914299A2 (en) | 2008-04-23 |
| EP1914299A3 (en) | 2008-05-21 |
| US7883712B2 (en) | 2011-02-08 |
| CA2481318A1 (en) | 2003-10-16 |
| CA2481318C (en) | 2014-06-10 |
| US20120189662A1 (en) | 2012-07-26 |
| HK1059803A1 (en) | 2004-07-16 |
| EP2302033A2 (en) | 2011-03-30 |
| EP1914299B1 (en) | 2011-11-30 |
| US20050220811A1 (en) | 2005-10-06 |
| PT1350839E (pt) | 2010-08-12 |
| WO2003085098A3 (en) | 2004-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1350839T3 (da) | Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti | |
| BR112021018694A2 (pt) | Vesículas extracelulares para distribuição de vacina | |
| SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| NZ759686A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| WO2008112344A3 (en) | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins | |
| MY149604A (en) | C.perfringens alpha toxoid vaccine | |
| MX2007003402A (es) | Composicion inmunogena para su uso en vacunacion contra estafilococos. | |
| TW200722101A (en) | Novel composition | |
| EP2562183A8 (en) | Novel immunogenic epitopes for immunotherapy | |
| PH12014501103A1 (en) | Methods of treating epidermal growth factor deletion mutant viii related disorders | |
| WO2008057235A3 (en) | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | |
| GB2434367A (en) | Improved vaccines | |
| WO2006081323A3 (en) | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin | |
| WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
| EA200701128A1 (ru) | Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы | |
| WO2005030136A3 (en) | Tumor vaccine | |
| MY146106A (en) | Antiallergic vaccine composition, method for its preparation and use in the treatment of allergic diseases | |
| WO2006117538A3 (en) | Assays for diagnosis of tuberculosis and uses thereof | |
| WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
| Lu et al. | Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy | |
| Dietrich et al. | Novel vaccination strategies based on recombinant Mycobacterium bovis BCG | |
| Ocampo | Vaccines-Recent advances and clinical trials | |
| DK1742656T3 (da) | Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine | |
| DE60325586D1 (de) | Mycobakterielle Proteinantigene für Krebstherapie und Impfung | |
| WO2005023295A3 (en) | Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use |